肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

西安交大二附院临床研究在美国引广泛关注

2017-06-20 雷恺 央广网

临床研究西安交大
关注

记者近日从西安交通大学第二附属医院获悉，西安交大二附院等联合开展的CAR-T治疗多发性骨髓瘤研究在美国临床肿瘤学会年会上引起广泛关注。这项研究的作者、西安交通大学第二附属医院的赵万红教授在一年一度的国际肿瘤学界盛会——美国临床肿瘤学会(ASCO)年会上介绍这项取得显着疗效的新型免疫治疗研究说，CAR-T是一种患者定制式治疗，即收集患者自身的T细胞，在体外进行基因重组，再回输到患者体内。基因重组的过

记者近日从西安交通大学第二附属医院获悉，西安交大二附院等联合开展的CAR-T治疗多发性骨髓瘤研究在美国临床肿瘤学会年会上引起广泛关注。

这项研究的作者、西安交通大学第二附属医院的赵万红教授在一年一度的国际肿瘤学界盛会——美国临床肿瘤学会(ASCO)年会上介绍这项取得显着疗效的新型免疫治疗研究说，CAR-T是一种患者定制式治疗，即收集患者自身的T细胞，在体外进行基因重组，再回输到患者体内。基因重组的过程包括在T细胞基因组中插入人工修饰的指定基因，这个基因将有助于基因重组后的T细胞找到并摧毁机体内的肿瘤细胞。

据介绍，介绍，这项研究未来计划在中国4家参与的医院纳入100例患者，并且在2018年初，计划在美国开展相似的临床研究，研究者希望能够在新发的多发性骨髓瘤患者中探索BCMA CAR-T治疗可能带来的临床获益。也希望中美两国之间的临床研究能够更多相互促进，加速生物治疗在我国的健康发展。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1985574, encodeId=813119855e4b9, content=<a href='/topic/show?id=7f68904898a' target=_blank style='color:#2F92EE;'>#西安交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90489, encryptionId=7f68904898a, topicName=西安交大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Fri Dec 01 11:59:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213372, encodeId=036d2133e2b0, content=学习了，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEJWOf8El7MfqtlSpy4eWtPl5cxmNJ4ezwbFf5vtCeh53ITyabFpFIJfKTPlzdh6ibOibVONwHUbm9/0, createdBy=a4351715107, createdName=人间可客, createdTime=Wed Jun 21 07:29:15 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213165, encodeId=42f421316595, content=目前看到在淋巴瘤中疗效还可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue Jun 20 17:05:27 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213164, encodeId=ae98213164db, content=这样的研究很值得继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhZvcea3VXGzHHZjyTumk8tqrxvCtkmw9tcickLiaMH2CiaNIYtgNayJyDVlUpMmVNVbmTppRRmUdr42/0, createdBy=bd2f2004134, createdName=迷茫的我, createdTime=Tue Jun 20 16:59:31 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213115, encodeId=9d6a213115e4, content=学习，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue Jun 20 11:51:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213106, encodeId=7df62131067b, content=多做些实在的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jun 20 11:23:57 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213104, encodeId=a231213104f1, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=28d72072417, createdName=我是谁？？, createdTime=Tue Jun 20 11:23:14 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-12-01 12498cbcm00(暂无昵称)

    #西安交大#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1985574, encodeId=813119855e4b9, content=<a href='/topic/show?id=7f68904898a' target=_blank style='color:#2F92EE;'>#西安交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90489, encryptionId=7f68904898a, topicName=西安交大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Fri Dec 01 11:59:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213372, encodeId=036d2133e2b0, content=学习了，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEJWOf8El7MfqtlSpy4eWtPl5cxmNJ4ezwbFf5vtCeh53ITyabFpFIJfKTPlzdh6ibOibVONwHUbm9/0, createdBy=a4351715107, createdName=人间可客, createdTime=Wed Jun 21 07:29:15 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213165, encodeId=42f421316595, content=目前看到在淋巴瘤中疗效还可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue Jun 20 17:05:27 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213164, encodeId=ae98213164db, content=这样的研究很值得继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhZvcea3VXGzHHZjyTumk8tqrxvCtkmw9tcickLiaMH2CiaNIYtgNayJyDVlUpMmVNVbmTppRRmUdr42/0, createdBy=bd2f2004134, createdName=迷茫的我, createdTime=Tue Jun 20 16:59:31 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213115, encodeId=9d6a213115e4, content=学习，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue Jun 20 11:51:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213106, encodeId=7df62131067b, content=多做些实在的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jun 20 11:23:57 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213104, encodeId=a231213104f1, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=28d72072417, createdName=我是谁？？, createdTime=Tue Jun 20 11:23:14 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-21 人间可客

    学习了，谢谢分享！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1985574, encodeId=813119855e4b9, content=<a href='/topic/show?id=7f68904898a' target=_blank style='color:#2F92EE;'>#西安交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90489, encryptionId=7f68904898a, topicName=西安交大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Fri Dec 01 11:59:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213372, encodeId=036d2133e2b0, content=学习了，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEJWOf8El7MfqtlSpy4eWtPl5cxmNJ4ezwbFf5vtCeh53ITyabFpFIJfKTPlzdh6ibOibVONwHUbm9/0, createdBy=a4351715107, createdName=人间可客, createdTime=Wed Jun 21 07:29:15 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213165, encodeId=42f421316595, content=目前看到在淋巴瘤中疗效还可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue Jun 20 17:05:27 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213164, encodeId=ae98213164db, content=这样的研究很值得继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhZvcea3VXGzHHZjyTumk8tqrxvCtkmw9tcickLiaMH2CiaNIYtgNayJyDVlUpMmVNVbmTppRRmUdr42/0, createdBy=bd2f2004134, createdName=迷茫的我, createdTime=Tue Jun 20 16:59:31 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213115, encodeId=9d6a213115e4, content=学习，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue Jun 20 11:51:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213106, encodeId=7df62131067b, content=多做些实在的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jun 20 11:23:57 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213104, encodeId=a231213104f1, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=28d72072417, createdName=我是谁？？, createdTime=Tue Jun 20 11:23:14 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-20 cqykthl

    目前看到在淋巴瘤中疗效还可以

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1985574, encodeId=813119855e4b9, content=<a href='/topic/show?id=7f68904898a' target=_blank style='color:#2F92EE;'>#西安交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90489, encryptionId=7f68904898a, topicName=西安交大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Fri Dec 01 11:59:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213372, encodeId=036d2133e2b0, content=学习了，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEJWOf8El7MfqtlSpy4eWtPl5cxmNJ4ezwbFf5vtCeh53ITyabFpFIJfKTPlzdh6ibOibVONwHUbm9/0, createdBy=a4351715107, createdName=人间可客, createdTime=Wed Jun 21 07:29:15 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213165, encodeId=42f421316595, content=目前看到在淋巴瘤中疗效还可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue Jun 20 17:05:27 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213164, encodeId=ae98213164db, content=这样的研究很值得继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhZvcea3VXGzHHZjyTumk8tqrxvCtkmw9tcickLiaMH2CiaNIYtgNayJyDVlUpMmVNVbmTppRRmUdr42/0, createdBy=bd2f2004134, createdName=迷茫的我, createdTime=Tue Jun 20 16:59:31 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213115, encodeId=9d6a213115e4, content=学习，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue Jun 20 11:51:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213106, encodeId=7df62131067b, content=多做些实在的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jun 20 11:23:57 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213104, encodeId=a231213104f1, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=28d72072417, createdName=我是谁？？, createdTime=Tue Jun 20 11:23:14 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-20 迷茫的我

    这样的研究很值得继续

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1985574, encodeId=813119855e4b9, content=<a href='/topic/show?id=7f68904898a' target=_blank style='color:#2F92EE;'>#西安交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90489, encryptionId=7f68904898a, topicName=西安交大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Fri Dec 01 11:59:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213372, encodeId=036d2133e2b0, content=学习了，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEJWOf8El7MfqtlSpy4eWtPl5cxmNJ4ezwbFf5vtCeh53ITyabFpFIJfKTPlzdh6ibOibVONwHUbm9/0, createdBy=a4351715107, createdName=人间可客, createdTime=Wed Jun 21 07:29:15 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213165, encodeId=42f421316595, content=目前看到在淋巴瘤中疗效还可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue Jun 20 17:05:27 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213164, encodeId=ae98213164db, content=这样的研究很值得继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhZvcea3VXGzHHZjyTumk8tqrxvCtkmw9tcickLiaMH2CiaNIYtgNayJyDVlUpMmVNVbmTppRRmUdr42/0, createdBy=bd2f2004134, createdName=迷茫的我, createdTime=Tue Jun 20 16:59:31 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213115, encodeId=9d6a213115e4, content=学习，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue Jun 20 11:51:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213106, encodeId=7df62131067b, content=多做些实在的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jun 20 11:23:57 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213104, encodeId=a231213104f1, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=28d72072417, createdName=我是谁？？, createdTime=Tue Jun 20 11:23:14 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-20 执着追梦

    学习，谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1985574, encodeId=813119855e4b9, content=<a href='/topic/show?id=7f68904898a' target=_blank style='color:#2F92EE;'>#西安交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90489, encryptionId=7f68904898a, topicName=西安交大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Fri Dec 01 11:59:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213372, encodeId=036d2133e2b0, content=学习了，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEJWOf8El7MfqtlSpy4eWtPl5cxmNJ4ezwbFf5vtCeh53ITyabFpFIJfKTPlzdh6ibOibVONwHUbm9/0, createdBy=a4351715107, createdName=人间可客, createdTime=Wed Jun 21 07:29:15 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213165, encodeId=42f421316595, content=目前看到在淋巴瘤中疗效还可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue Jun 20 17:05:27 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213164, encodeId=ae98213164db, content=这样的研究很值得继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhZvcea3VXGzHHZjyTumk8tqrxvCtkmw9tcickLiaMH2CiaNIYtgNayJyDVlUpMmVNVbmTppRRmUdr42/0, createdBy=bd2f2004134, createdName=迷茫的我, createdTime=Tue Jun 20 16:59:31 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213115, encodeId=9d6a213115e4, content=学习，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue Jun 20 11:51:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213106, encodeId=7df62131067b, content=多做些实在的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jun 20 11:23:57 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213104, encodeId=a231213104f1, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=28d72072417, createdName=我是谁？？, createdTime=Tue Jun 20 11:23:14 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-20 楠博One

    多做些实在的研究

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1985574, encodeId=813119855e4b9, content=<a href='/topic/show?id=7f68904898a' target=_blank style='color:#2F92EE;'>#西安交大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90489, encryptionId=7f68904898a, topicName=西安交大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Fri Dec 01 11:59:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213372, encodeId=036d2133e2b0, content=学习了，谢谢分享！, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEJWOf8El7MfqtlSpy4eWtPl5cxmNJ4ezwbFf5vtCeh53ITyabFpFIJfKTPlzdh6ibOibVONwHUbm9/0, createdBy=a4351715107, createdName=人间可客, createdTime=Wed Jun 21 07:29:15 CST 2017, time=2017-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213165, encodeId=42f421316595, content=目前看到在淋巴瘤中疗效还可以, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NdicLmdJEK9VoiaDianY6fzHNN9iaGv80m39pMHU3eSnNN0kn1o0rdQ7Bz2f03Qibcf1ia7rKvxIt4UVlErF2d4gCmDC5/0, createdBy=98e31740255, createdName=cqykthl, createdTime=Tue Jun 20 17:05:27 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213164, encodeId=ae98213164db, content=这样的研究很值得继续, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhZvcea3VXGzHHZjyTumk8tqrxvCtkmw9tcickLiaMH2CiaNIYtgNayJyDVlUpMmVNVbmTppRRmUdr42/0, createdBy=bd2f2004134, createdName=迷茫的我, createdTime=Tue Jun 20 16:59:31 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213115, encodeId=9d6a213115e4, content=学习，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyhb9xDeHojCicsdRdyC3XXdGk2ib9yLypZuHN06WeW4HO8WN0GGrgEfvnTX8gsckof05GHOU5OM4Mvx/0, createdBy=9cee1982656, createdName=执着追梦, createdTime=Tue Jun 20 11:51:56 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213106, encodeId=7df62131067b, content=多做些实在的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/05/25/aee510ed68ce4736e9fe4ec7d03c01b1.jpg, createdBy=ce892064652, createdName=楠博One, createdTime=Tue Jun 20 11:23:57 CST 2017, time=2017-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=213104, encodeId=a231213104f1, content=学习了。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo51eheDrP8dFkRicVB5LyaVk2Nc1S87J8nCBgASWQ4rrorsyzzr0UzN8N5bibeqGofE7ZtdT6YNZHEQ/0, createdBy=28d72072417, createdName=我是谁？？, createdTime=Tue Jun 20 11:23:14 CST 2017, time=2017-06-20, status=1, ipAttribution=)]
    2017-06-20 我是谁？？

    学习了。。。。。

    0

相关资讯

Ann Surg：虞先浚教授团队发表“CA19-9假阴性”胰腺癌人群鉴定研究成果

近日，复旦大学附属肿瘤医院胰腺外科虞先浚教授团队关于“CA19-9假阴性”胰腺癌人群鉴定的相关研究在《外科学年鉴》（Annuals of Surgery）上发表。糖类抗原19-9（CA19-9）是目前公认的在胰腺癌的筛查、诊断、预后判断以及治疗指导中最为重要的肿瘤标志物。这一抗原最早被单克隆抗体116NS19-9识别，并在临床中广泛使用，因此命名为CA19-9。CA19-9水平的变化可以提示胰腺癌

JAMA：美国国家科学院人类基因编辑原则

美国国家科学院报告对与人类基因组编辑相关的专业设置、编辑监督与应用提出建议

Clin Implant Dent Relat Res：哪种颈部结构的种植体更佳？

随着种植技术的成熟，种植牙应用越发广泛。种植体颈部设计以及种植体-基台界面的差异可以改变种植体周围骨水平。如何选择不同颈部形态的种植体呢？不同颈部形态种植体的预后有何不同？

The Lancet Oncology：Ipilimumab用于不可切除或转移性黑素瘤

对于晚期黑色素瘤患者，10mg/kg的ipilimumab比3mg/kg的剂量能显着延长患者的生存期但与治疗相关的不良事件发生率也随之增加。

NEJM：使用C1抑制剂预防遗传性血管性水肿

遗传性血管性水肿是致残的，潜在致命的疾病，是C1抑制蛋白的缺失（I型）或功能障碍（II型）所造成的的。皮下注射来抑CS1830可抑制C1活性提供有效的疾病预防手段。

Lancet Oncol：PD-1免疫治疗药物能有效治疗恶性胸膜间皮瘤 (KEYNOTE-028)

现有的称为彭博瑞珠单抗的免疫治疗药物似乎有效治疗恶性胸膜间皮瘤，这是一种罕见且侵袭性的肺癌，主要是由暴露于石棉引起的。在“柳叶刀肿瘤学”杂志上，研究人员描述了使用抗体药物对这种罕见癌症的阳性结果的第一项研究。医生检查胸部 X 光片研究结果表明，免疫治疗药物显示出对恶性胸膜间皮瘤的二线治疗有希望，这是一种由暴露于石棉导致的罕见和侵袭性肺癌。